Search

Your search keyword '"Malta, Fernanda de Mello"' showing total 34 results
Start Over Author "Malta, Fernanda de Mello"
34 results on '"Malta, Fernanda de Mello"'

1. Evidence of reassortment of avian influenza A (H2) viruses in Brazilian shorebirds

Author

Thomazelli, Luciano M., primary, Pinho, João Renato Rebello, additional, Dorlass, Erick G., additional, Ometto, Tatiana, additional, Meneguin, Carla, additional, Paludo, Danielle, additional, Frias, Rodolfo Teixeira, additional, Mancini, Patricia Luciano, additional, Monteiro, Cairo, additional, Aicher, Sophie Marie, additional, Walker, David, additional, Scagion, Guilherme P., additional, Krauss, Scott, additional, Fabrizio, Thomas, additional, Petry, Maria Virgínia, additional, Scherer, Angelo L., additional, Scherer, Janete, additional, Serafini, Patricia P., additional, Neto, Isaac S., additional, Amgarten, Deyvid Emanuel, additional, Malta, Fernanda de Mello, additional, Borges, Ana Laura Boechat, additional, Webster, Robert G., additional, Webby, Richard J., additional, Durigon, Edison L., additional, and de Araujo, Jansen, additional

Published
2024
Full Text
View/download PDF

5. Sabia Virus-Like Mammarenavirus in Patient with Fatal Hemorrhagic Fever, Brazil, 2020

Author

Malta, Fernanda de Mello, Amgarten, Deyvid, Nastri, Ana Catharina de Seixas Santos, Ho, Yeh-Li, Casadio, Luciana Vilas Boas, Basqueira, Marcela, Selegatto, Gloria, Cervato, Murilo Castro, Duarte-Neto, Amaro Nunes, Higashino, Hermes Ryoiti, Medeiros, Felipe Arthur Faustino, Gendler, Jose Luiz Pinto Lima, Levin, Anna S., and Pinho, Joao Renato Rebello

Subjects
Yellow fever, Hemorrhagic fevers, Infection, Health
Abstract

Viral infections have become an important public health issue in South America during the past 2 decades. Outbreaks of arboviral disease, such as dengue, chikungunya, Zika, and yellow fever, have [...]

Published
2020

6. Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020–2022

Author

Marra, Alexandre R., Sampaio, Vanderson Souza, Ozahata, Mina Cintho, Lopes, Rafael, Brito, Anderson F., Bragatte, Marcelo, Kalil, Jorge, Miraglia, João Luiz, Malheiro, Daniel Tavares, Guozhang, Yang, Teich, Vanessa Damazio, Victor, Elivane da Silva, Pinho, João Renato Rebello, Cypriano, Adriana, Vieira, Laura Wanderly, Polonio, Miria, de Oliveira, Solange Miranda, Ricardo, Victória Catharina Volpe, Maezato, Aline Miho, Callado, Gustavo Yano, Schettino, Guilherme de Paula Pinto, de Oliveira, Ketti Gleyzer, Santana, Rúbia Anita Ferraz, Malta, Fernanda de Mello, Amgarten, Deyvid, Boechat, Ana Laura, Kobayashi, Takaaki, Perencevich, Eli, Edmond, Michael B., and Rizzo, Luiz Vicente

Abstract

AbstractObjective:To determine risk factors for the development of long coronavirus disease 2019 (COVID-19) in healthcare personnel (HCP).Methods:We conducted a case–control study among HCP who had confirmed symptomatic COVID-19 working in a Brazilian healthcare system between March 1, 2020, and July 15, 2022. Cases were defined as those having long COVID according to the Centers for Disease Control and Prevention definition. Controls were defined as HCP who had documented COVID-19 but did not develop long COVID. Multiple logistic regression was used to assess the association between exposure variables and long COVID during 180 days of follow-up.Results:Of 7,051 HCP diagnosed with COVID-19, 1,933 (27.4%) who developed long COVID were compared to 5,118 (72.6%) who did not. The majority of those with long COVID (51.8%) had 3 or more symptoms. Factors associated with the development of long COVID were female sex (OR, 1.21; 95% CI, 1.05–1.39), age (OR, 1.01; 95% CI, 1.00–1.02), and 2 or more SARS-CoV-2 infections (OR, 1.27; 95% CI, 1.07–1.50). Those infected with the SARS-CoV-2 δ (delta) variant (OR, 0.30; 95% CI, 0.17–0.50) or the SARS-CoV-2 o (omicron) variant (OR, 0.49; 95% CI, 0.30–0.78), and those receiving 4 COVID-19 vaccine doses prior to infection (OR, 0.05; 95% CI, 0.01–0.19) were significantly less likely to develop long COVID.Conclusions:Long COVID can be prevalent among HCP. Acquiring >1 SARS-CoV-2 infection was a major risk factor for long COVID, while maintenance of immunity via vaccination was highly protective.

Published
2023
Full Text
View/download PDF

8. Risk factors for long COVID among healthcare workers, Brazil, 2020–2022

Author

Marra, Alexandre R., primary, Sampaio, Vanderson Souza, additional, Ozahata, Mina Cintho, additional, da Silva, Rafael Lopes Paixão, additional, Brito, Anderson, additional, Bragatte, Marcelo, additional, Kalil, Jorge, additional, Miraglia, João Luiz, additional, Malheiros, Daniel Tavares, additional, Guozhang, Yang, additional, Teich, Vanessa Damazio, additional, Victor, Elivane da Silva, additional, Pinho, João Renato Rebello, additional, Cypriano, Adriana, additional, Vieira, Laura Wanderly, additional, Polonio, Miria, additional, de Oliveira, Solange Miranda, additional, Ricardo, Victória Catharina Volpe, additional, Maezato, Aline Miho, additional, Callado, Gustavo Yano, additional, Schettino, Guilherme de Paula Pinto, additional, de Oliveira, Ketti Gleyzer, additional, Santana, Rúbia Anita Ferraz, additional, Malta, Fernanda de Mello, additional, Amgarten, Deyvid, additional, Boechat, Ana Laura, additional, Kobayashi, Takaaki, additional, Perencevich, Eli, additional, Edmond, Michael B., additional, and Rizzo, Luiz Vicente, additional

Published
2023
Full Text
View/download PDF

9. Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil

Author

Marra, Alexandre R., primary, Miraglia, João Luiz, additional, Malheiro, Daniel Tavares, additional, Guozhang, Yang, additional, Teich, Vanessa Damazio, additional, Victor, Elivane da Silva, additional, Pinho, João Renato Rebello, additional, Cypriano, Adriana, additional, Vieira, Laura Wanderly, additional, Polonio, Miria, additional, Ornelas, Rafael Herrera, additional, de Oliveira, Solange Miranda, additional, Borges, Flavio Araujo, additional, Oler, Silvia Cristina Cassiano, additional, Ricardo, Victória Catharina Volpe, additional, Maezato, Aline Miho, additional, Callado, Gustavo Yano, additional, Schettino, Guilherme de Paula Pinto, additional, de Oliveira, Ketti Gleyzer, additional, Santana, Rúbia Anita Ferraz, additional, Malta, Fernanda de Mello, additional, Amgarten, Deyvid, additional, Boechat, Ana Laura, additional, Kobayashi, Takaaki, additional, Salinas, Jorge L., additional, Edmond, Michael B., additional, and Rizzo, Luiz Vicente, additional

Published
2023
Full Text
View/download PDF

10. Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021.

Author

Marra, Alexandre R, Miraglia, João Luiz, Malheiros, Daniel Tavares, Guozhang, Yang, Teich, Vanessa Damazio, Victor, Elivane da Silva, Pinho, João Renato Rebello, Cypriano, Adriana, Vieira, Laura Wanderly, Polonio, Miria, Ornelas, Rafael Herrera, Oliveira, Solange Miranda de, Junior, Flavio Araujo Borges, Oler, Silvia Cristina Cassiano, Schettino, Guilherme de Paula Pinto, Oliveira, Ketti Gleyzer de, Santana, Rúbia Anita Ferraz, Malta, Fernanda de Mello, Amgarten, Deyvid, and Boechat, Ana Laura

Subjects
DRUG efficacy, COVID-19, COVID-19 vaccines, RETROSPECTIVE studies, DISEASE incidence, COMPARATIVE studies, MESSENGER RNA, DESCRIPTIVE statistics, RESEARCH funding, LONGITUDINAL method, POISSON distribution
Abstract

Background Little is currently known about vaccine effectiveness (VE) for either 2 doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac (Instituto Butantan) inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare workers (HCWs). Methods We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil from January to December 2021. VE was defined as 1 – incidence rate ratio (IRR), with IRR determined using Poisson models with the occurrence of laboratory-confirmed coronavirus disease 2019 (COVID-19) infection as the outcome, adjusting for age, sex, and job type. We compared those receiving viral vector or inactivated viral primary series (2 doses) with those who received an mRNA booster. Results A total of 11 427 HCWs met the inclusion criteria. COVID-19 was confirmed in 31.5% of HCWs receiving 2 doses of CoronaVac vaccine versus 0.9% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster (P <.001) and 9.8% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 1% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster (P <.001). In the adjusted analyses, the estimated VE was 92.0% for 2 CoronaVac vaccines plus mRNA booster and 60.2% for 2 ChAdOx1 vaccines plus mRNA booster, when compared with those with no mRNA booster. Of 246 samples screened for mutations, 191 (77.6%) were Delta variants. Conclusions While 2 doses of ChAdOx1 or CoronaVac vaccines prevent COVID-19, the addition of a Pfizer/BioNTech booster provided significantly more protection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. METAGENÔMICA RNA EM AMOSTRAS DE LÍQUIDO CEFALORRAQUIDIANO: RESULTADOS DE UM LABORATÓRIO PRIVADO NA CIDADE DE SÃO PAULO

Author

Petroni, Roberta Cardoso, Santos, Anelisie da Silva, Menezes, Marcio Anunciação, Salles, Ana Paula Moreira, Takara, Alexandre Hideaki, Malta, Fernanda de Mello, Amgarten, Deyvid Emanuel, Franco, Raquel Riyuzo de Almeida, Villarinho, Andrea Ap. Rocco, Santana, Rubia Anita Ferraz, Doi, Andre Mario, Fernandes, Gustavo Bruniera Peres, and Pinho, João Renato Rebello

Published
2022
Full Text
View/download PDF

12. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis

Author

Santos, Ana Paula de Torres, primary, Silva, Vanessa Cristina Martins, additional, Mendes-Corrêa, Maria Cássia, additional, Lemos, Marcilio Figueiredo, additional, Malta, Fernanda de Mello, additional, Santana, Rúbia Anita Ferraz, additional, Dastoli, Gregório Tadeu Fernando, additional, Castro, Vanessa Fusco Duarte de, additional, Pinho, João Renato Rebello, additional, and Moreira, Regina Célia, additional

Published
2022
Full Text
View/download PDF

15. Characterization of Primary Direct Acting Antiviral Drugs (DAA) Resistance Mutations in NS5A/NS5B Regions of Hepatitis C Virus with Genotype 1a and 1b from Patients with Chronic Hepatitis

Author

Santos, Ana Paula de Torres, primary, Silva, Vanessa Cristina Martins, additional, Mendes-Corrêa, Maria Cássia J, additional, Lemos, Marcilio Figueiredo, additional, Malta, Fernanda de Mello, additional, Santana, Rúbia Anita Ferraz, additional, Dastoli, Gregório Tadeu Fernando, additional, de Castro, Vanessa Fusco Duarte, additional, Pinho, João Renato Rebello, additional, and Moreira, Regina Célia, additional

Published
2021
Full Text
View/download PDF

16. Genomic Characterization of mcr-1.1-Producing Escherichia coli Recovered From Human Infections in São Paulo, Brazil

Author

Girardello, Raquel, primary, Piroupo, Carlos Morais, additional, Martins, Joaquim, additional, Maffucci, Marcia Helena, additional, Cury, Ana Paula, additional, Franco, Maria Renata Gomes, additional, Malta, Fernanda de Mello, additional, Rocha, Natália Conceição, additional, Pinho, João Renato Rebello, additional, Rossi, Flavia, additional, Duarte, Alberto José da Silva, additional, and Setubal, João Carlos, additional

Published
2021
Full Text
View/download PDF

18. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

Author

Araujo, Danielle Bastos, primary, Machado, Rafael Rahal Guaragna, additional, Amgarten, Deyvid Emanuel, additional, Malta, Fernanda de Mello, additional, de Araujo, Gabriel Guarany, additional, Monteiro, Cairo Oliveira, additional, Candido, Erika Donizetti, additional, Soares, Camila Pereira, additional, de Menezes, Fernando Gatti, additional, Pires, Ana Carolina Cornachioni, additional, Santana, Rúbia Anita Ferraz, additional, Viana, Amanda de Oliveira, additional, Dorlass, Erick, additional, Thomazelli, Luciano, additional, Ferreira, Luis Carlos de Sousa, additional, Botosso, Viviane Fongaro, additional, Carvalho, Cristiane Rodrigues Guzzo, additional, Oliveira, Danielle Bruna Leal, additional, Pinho, João Renato Rebello, additional, and Durigon, Edison Luiz, additional

Published
2020
Full Text
View/download PDF

20. Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)

Author

Figueiredo-Mello, Claudia, primary, Casadio, Luciana Vilas Boas, additional, Avelino-Silva, Vivian Iida, additional, Yeh-Li, Ho, additional, Sztajnbok, Jaques, additional, Joelsons, Daniel, additional, Antonio, Marilia Bordignon, additional, Pinho, João Renato Rebello, additional, Malta, Fernanda de Mello, additional, Gomes-Gouvêa, Michele Soares, additional, Salles, Ana Paula Moreira, additional, Corá, Aline Pivetta, additional, Moreira, Carlos Henrique Valente, additional, Ribeiro, Ana Freitas, additional, Nastri, Ana Catharina de Seixas Santos, additional, Malaque, Ceila Maria Sant'Ana, additional, Teixeira, Ralcyon Francis Azevedo, additional, Borges, Luciana Marques Sansão, additional, Gonzalez, Mario Peribañez, additional, Junior, Luiz Carlos Pereira, additional, Souza, Tâmara Newman Lobato, additional, Song, Alice Tung Wan, additional, D'Albuquerque, Luiz Augusto Carneiro, additional, Abdala, Edson, additional, Andraus, Wellington, additional, Martino, Rodrigo Bronze de, additional, Ducatti, Liliana, additional, Andrade, Guilherme Marques, additional, Malbouisson, Luiz Marcelo Sá, additional, Souza, Izabel Marcilio de, additional, Carrilho, Flair José, additional, Sabino, Ester Cerdeira, additional, and Levin, Anna S, additional

Published
2019
Full Text
View/download PDF

21. Liver Transplantation for Fulminant Hepatitis Attributed to Yellow Fever

Author

Song, Alice Tung Wan, primary, Abdala, Edson, additional, de Martino, Rodrigo Bronze, additional, Malbouisson, Luis Marcelo Sá, additional, Tanigawa, Ryan Yukimatsu, additional, Andrade, Guilherme Marques, additional, Ducatti, Liliana, additional, Doi, Andre Mario, additional, Pinho, João Renato Rebello, additional, Gomes‐Gouvêa, Michele Soares, additional, Malta, Fernanda de Mello, additional, Arantes, Rubens Macedo, additional, Tonacio, Adriana Coracini, additional, Figueira Pinto, Lécio, additional, Haddad, Luciana Bertocco Paiva, additional, Santos, Vinicius Rocha, additional, Pinheiro, Rafael Soares Nunes, additional, Nacif, Lucas Souto, additional, Galvão, Flávio Henrique Ferreira, additional, Alves, Venancio Avancini Ferreira, additional, Andraus, Wellington, additional, and Carneiro D’Albuquerque, Luiz Augusto, additional

Published
2019
Full Text
View/download PDF

22. Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases

Author

Casadio, Luciana Vilas Boas, primary, Salles, Ana Paula Moreira, additional, Malta, Fernanda de Mello, additional, Leite, Gabriel Fialkovitz, additional, Ho, Yeh-Li, additional, Gomes-Gouvêa, Michele Soares, additional, Malbouisson, Luiz Marcelo Sá, additional, Levin, Anna S, additional, de Azevedo Neto, Raymundo Soares, additional, Carrilho, Flair José, additional, Nastri, Ana Catharina Seixas Santos, additional, and Pinho, João Renato Rebello, additional

Published
2019
Full Text
View/download PDF

23. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil.

Author

Santos, Ana Paula de Torres, Silva, Vanessa Cristina Martins, Mendes-Corrêa, Maria Cássia, Lemos, Marcilio Figueiredo, Malta, Fernanda de Mello, Santana, Rúbia Anita Ferraz, Dastoli, Gregório Tadeu Fernando, Castro, Vanessa Fusco Duarte de, Pinho, João Renato Rebello, and Moreira, Regina Célia

Subjects
HEPATITIS C, GENE amplification, HEPATITIS, GENOTYPES, POLYMERASE chain reaction, PUBLIC health, GENES, HEPATITIS B
Abstract

Purpose: Globally, it is estimated that 71 million people are chronically infected with hepatitis C, and 10– 20% of these will develop cirrhosis and hepatocellular carcinoma. The development of new direct-acting antiviral (DAA) drugs has contributed to sustained virological response (SVR), eliminating the infection and achieving cure of chronic hepatitis C. However, treated patients can develop HCV resistance to DAAs, which can contribute to the failure of treatment. Here, we aimed to evaluate the prevalence and specific pattern of NS5A and NS5B resistance-associated substitutions (RAS) in samples from patients chronically infected with HCV genotype 3a at a public health laboratory, Instituto Adolfo Lutz, São Paulo, Brazil. Patients and Methods: Serum samples from the enrolled individuals were submitted to "in-house" polymerase chain reaction amplification of NS5A and NS5B non-structural protein genes, which were then sequenced by Sanger method. Results: A total of 170 and 190 samples were amplified and analyzed for NS5A and NS5B, respectively. For NS5A, 20 (12.0%) samples showed some important RAS; 16 (9.0%) showed some type of substitution and 134 (79.0%) showed no polymorphism. No sample showed any RAS for NS5B. Conclusion: This study found important RAS in samples from naïve chronic HCV patients in some areas from São Paulo. The most prevalent were A62S, A30K, and Y93H, which could indicate an increase in resistance to some DAAs used in HCV treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases

Author

Chachá, Silvana Gama Florencio, primary, Gomes-Gouvêa, Michele Soares, additional, Malta, Fernanda de Mello, additional, Ferreira, Sandro da Costa, additional, Villanova, Márcia Guimarães, additional, Souza, Fernanda Fernandes, additional, Teixeira, Andreza Correa, additional, Passos, Afonso Dinis da Costa, additional, Pinho, João Renato Rebello, additional, and Martinelli, Ana de Lourdes Candolo, additional

Published
2017
Full Text
View/download PDF

25. Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up

Author

Machado, Soraia Mafra, primary, Almeida Neto, Cesar de, additional, Pinho, João Renato Rebello, additional, Malta, Fernanda de Mello, additional, Capuani, Ligia, additional, Campos, Aléia Faustina, additional, Abreu, Fatima Regina Marques, additional, Nastri, Ana Catharina de Seixas Santos, additional, Santana, Rúbia Anita Ferraz, additional, Sabino, Ester Cerdeira, additional, and Mendes-Correa, Maria Cássia, additional

Published
2017
Full Text
View/download PDF

26. Sofosbuvir inhibits yellow fever virus in vitroand in patients with acute liver failure

Author

Mendes, Érica Araújo, Pilger, Denise Regina Bairros de, Santos Nastri, Ana Catharina de Seixas, Malta, Fernanda de Mello, Pascoalino, Bruno dos Santos, Carneiro D’Albuquerque, Luiz Augusto, Balan, Andrea, Freitas, Lucio Holanda Gondim de, Durigon, Edison Luis, Carrilho, Flair José, and Rebello Pinho, João Renato

Abstract

Direct antiviral agents (DAAs) are very efficient in inhibiting hepatitis C virus and might be used to treat infections caused by other flaviviruses whose worldwide detection has recently increased. The aim of this study was to verify the efficacy of DAAs in inhibiting yellow fever virus (YFV) by using drug repositioning (a methodology applied in the pharmaceutical industry to identify new uses for approved drugs).

Published
2019
Full Text
View/download PDF

27. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.

Author

Tavares, Rita Chelly Felix, Feldner, Ana Cristina de Castro, Pinho, João Renato Rebello, Malta, Fernanda de Mello, Carvalho-Filho, Roberto José, Santana, Rúbia Anita Ferraz, Castro, Vanessa Fusco Duarte de, Dastoli, Gregório Tadeu Fernando, Lima, Juliana Custódio, and Ferraz, Maria Lucia Cardoso Gomes

Subjects
ANTIVIRAL agents, HEMODIALYSIS, KIDNEY transplantation, HEPATITIS C virus, INTERFERONS
Abstract

Background: Direct-acting antiviral agents (DAAs) permit the use of interferon (IFN)-free regimens to treat hepatitis C (HCV) in patients with chronic kidney disease (CKD) on hemodialysis (HD) or renal transplant (RTx) recipients, with excellent response rates and safety. However, the occurrence of basal or therapy-induced resistance-associated substitutions (RASs) to DAAs can result in treatment failure. The aim of this study was to estimate the prevalence of RASs to NS3A, NS5A and NS5B inhibitors, and particularly the Q80K polymorphism, in CKD patients on HD and RTx recipients infected with HCV. Patients and methods: HD and RTx patients infected with HCV-genotype 1 (GT1) were subjected to sequencing of the NS3, NS5A and NS5B regions. Results: Direct sequencing of NS3 protease, NS5A and NS5B was performed in 76 patients (HD, n=37; RTx, n=39). The overall prevalence of RASs was 38.2%, but only 5.3% of the patients had mutations in more than one region. Substitutions were detected in NS3A (17.8%), NS5A (21.9%) and NS5B (8.4%). Q80K was detected in 1.5 % of the patients. Highly inhibitory RASs were uncommon (L31M, 2.6%; L159F+C316N, 2.6%). RASs were more prevalent in HCV-GT1a (42.9%) than in HCV-GT1b (32.4%), P=0.35. RASs were detected in 52.4% of treatment-naive patients and 27.8% of peg-IFN/ribavirin-experienced patients (P=0.12). The presence of RASs was associated with time of RTx (P=0.01). Conclusion: The Q80K polymorphism was uncommon in our sample of HD and RTx patients. Despite the high prevalence of naturally occurring RASs, most of the substitutions detected were associated with a low level of resistance to DAAs. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

28. Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer

Author

Moreira, João Paulo, primary, Malta, Fernanda de Mello, additional, Diniz, Márcio Augusto, additional, Kikuchi, Luciana, additional, Chagas, Aline Lopes, additional, Lima, Livia de Souza Botelho, additional, Gomes-Gouvêa, Michele Soares, additional, de Castro, Vanessa Fusco Duarte, additional, Santana, Rubia Anita Ferraz, additional, Sumita, Nairo Massakazu, additional, Paranagua Vezozzo, Denise Cerqueira, additional, Carrilho, Flair José, additional, and Pinho, João Renato Rebello, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results